Company — Trenchant Biosystems Trenchant Biosystems specializes in developing scalable and efficient cell therapy manufacturing technologies that streamline processes,
Private equity investments demand strategic growth, operational excellence, and measurable outcomes. At Trenchant, we specialize in helping businesses achieve Fully-Automated CAR-T Bioprocessing Platform Aids Scalability
Cancer cells video 1 As a result of the partnership, Trenchant BioSystems will integrate Autolomous' autoloMATE digital solution into its automated CGT manufacturing Philip Coelho - Chairman & CTO of Trenchant BioSystems, Inc
Cell and Gene Therapy Manufacturing Challenges & Solutions Trenchant Biosystems Trenchant Bio is making cell and gene therapies (CGT) more affordable and accessible to patients. We were founded in 2022 to create cell therapy manufacturing
Trenchant & Autolomous Partner to Accelerate Cell & Gene Therapy Trenchant BioSystems, tells GEN. CGT-in-a-box. To address those issues, Trenchant is developing a fully-automated cell therapy manufacturing The new industry deals progressing drug discovery - Drug Discovery
sunrise video Cells video 1 Addressing major obstacles in the development and manufacturing of CGTs with Jon Ellis, CEO of Trenchant BioSystems.
Trenchant, Inc. As a result of the partnership, Trenchant BioSystems will integrate Autolomous' autoloMATE digital solution into its automated manufacturing
Under the partnership, the companies will combine fully automated and digitalized technologies aimed at reducing CGT manufacturing timelines Supplier News: Fujifilm Irvine Scientific, Pace Life Sciences As a result of the partnership, Trenchant BioSystems will integrate Autolomous' autoloMATE digital solution into their automated CGT
Philip H. Coelho, currently serving as Chairman and CTO of Trenchant BioSystems, Inc. is an engineer/ inventor, educated at the University of California, Davis. Trenchant BioSystems and Autolomous to Combine Platforms for